Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flecainide/Modafinil - Theranexus

Drug Profile

Flecainide/Modafinil - Theranexus

Alternative Names: Modafinil/flecainide - Theranexus; THN-102

Latest Information Update: 30 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theranexus
  • Class Benzamides; Benzhydryl compounds; Class Ic antiarrhythmics; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Central nervous system stimulants; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypersomnia; Narcolepsy

Most Recent Events

  • 28 Feb 2019 Theranexus completes a phase II trial in Narcolepsy in France and Belgium (PO) (NCT02821715)
  • 16 Jul 2018 Phase-II clinical trials in Sleep disorders in USA (PO)
  • 26 Jun 2018 The German Medicines Agency approves clinical trial application for a phase II study in patients with Excessive daytime sleepiness (EDS) related to Parkinson's disease in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top